- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Reckitt Benckiser Pharms., Inc. v. Dr. Reddy’s Labs. S.A.
The court applied the dedicated disclosure rule to find no infringement.
October 20, 2017
Case Name: Reckitt Benckiser Pharms., Inc. v. Dr. Reddy’s Labs. S.A., No. 14-1451-RGA, 2017 U.S. Dist. LEXIS 140633 (D. Del. Aug 31, 2017) (Andrews, J.)
Drug Product and Patent(s)-in-Suit: Suboxone® (buprenorphine HCl / naloxone HCl); U.S. Patent No. 8,017,150 (“the ’150 patent”)
Nature of the Case and Issue(s) Presented: The ’150 patent covers Suboxone, a sublingual film used to treat opioid dependence. Plaintiffs, the holder of the ’150 patent and the patent’s exclusive licensee, brought suit against Defendants, alleging that Defendants’ generic product infringed the ’150 patent. In response, Defendants argued that their product did not infringe the ’150 patent and, even if it were to, the ’150 patent was invalid as obvious. The court agreed with Defendants that their product did not infringe the ’150 patent, but also found that Defendants had not met their burden in proving that the ’150 patent was obvious.
Why Defendants Prevailed: Reviewing the specification and the claims of the ’150 patent, the court determined that the patent claimed only the use of polyethylene oxide and hydrophobic cellulosic polymers, but the specification described polyvinyl pyrrolidone (“PVP”) as an alternative to hydrophobic cellulosic polymers. Because PVP was described in the specification but was not claimed, the court applied the dedicated disclosure rule from PSC Computer Prods., Inc. v. Foxconn Int’l, Inc., 355 F.3d 1353 (Fed. Cir. 2004). The dedicated disclosure rule provides that “if one of ordinary skill in the art can understand the unclaimed disclosed teaching upon reading the written description, the alternative matter disclosed has been dedicated to the public.” PSC, 355 F.3d at 1360. Thus, the court ruled that the use of PVP, as in the generic product, had been dedicated to the public and could not infringe the patent.
Having determined that the ’150 patent was not infringed, the court nevertheless performed a validity analysis of the patent. Because the cited prior art did not disclose the elements of the claims of the ’150 patent, and even taught away from the claimed invention, Defendants did not meet the burden to prove the ’150 patent invalid.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.